Investor Relations

Company Overview

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Stock Inforamtion

IR Contacts

Company

Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com

Investor Relations

T: 650-543-5470
ir@unicycive.com

Transfer Agent

Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.